Status:
COMPLETED
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Brief Summary
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-rela...
Eligibility Criteria
Inclusion
- Physician-diagnosed COPD
- Having been prescribed treatment with TRIXEO according to label and local market reimbursement criteria
- Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol
- After full explanation, patients must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.
Exclusion
- COPD due to α-1 antitrypsin deficiency
- Previous treatment with any other triple fixed-dose combination during screening
- Hospitalisation due to COPD exacerbation within the last 4 weeks prior to enrolment
- Pregnancy or lactation period
- Participation in an observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in a randomised clinical trial in the last 30 days.
- Patient still recovering from Covid-19 infection
Key Trial Info
Start Date :
March 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2024
Estimated Enrollment :
475 Patients enrolled
Trial Details
Trial ID
NCT05311306
Start Date
March 15 2022
End Date
July 16 2024
Last Update
July 1 2025
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Böblingen, Germany, Germany, 71032
2
Research Site
Doerfles-Esbach, Germany, Germany, 96487
3
Research Site
Fürstenwalde, Germany, Germany, 15517
4
Research Site
Marburrg, Germany, Germany, 35037